Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS-CoV-2 'long-haulers'? — CFSMEATLAS
Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS-CoV-2 'long-haulers'?
Wood, Emily, Hall, Katherine H, Tate, Warren · Chronic diseases and translational medicine · 2021 · DOI
Quick Summary
This study reviews research on how mitochondria (the energy-producing centers in our cells) and oxidative stress (cellular damage from harmful molecules) may contribute to ME/CFS and long COVID symptoms. The authors examine whether antioxidant treatments could help restore energy production and reduce fatigue in these conditions. They highlight that many COVID-19 long-haulers develop symptoms that look very similar to ME/CFS, suggesting they may share underlying biological causes.
Why It Matters
This study is important because it connects two patient populations—ME/CFS and long COVID—through a shared biological framework, potentially accelerating research into treatments for both. Understanding mitochondrial dysfunction and oxidative stress provides a testable mechanistic hypothesis that could guide future therapeutic development. The review emphasizes the urgency of research in this area given the large number of people affected by both conditions.
Observed Findings
Dysfunctional mitochondrial pathways have been documented in ME/CFS patients and appear relevant to chronic fatigue symptoms.
Oxidative stress markers and evidence of cellular damage from reactive oxygen species are elevated in some ME/CFS populations.
SARS-CoV-2 long-haulers develop chronic symptoms that closely resemble ME/CFS presentations.
Antioxidant compounds have theoretical potential to address oxidative stress in these conditions.
Inferred Conclusions
Mitochondrial dysfunction and oxidative stress represent plausible shared biological mechanisms in both ME/CFS and long COVID.
Antioxidant-based therapies merit urgent investigation as potential treatments targeting these pathways.
The phenotypic similarity between ME/CFS and post-COVID fatigue suggests common underlying pathophysiology.
Remaining Questions
Do antioxidant interventions improve mitochondrial function and reduce fatigue in controlled clinical trials?
Which specific antioxidant compounds or combinations are most effective, and what are optimal dosing strategies?
What initiates mitochondrial dysfunction in these conditions, and are there upstream interventions that could prevent it?
What This Study Does Not Prove
This literature review does not prove that mitochondrial dysfunction or oxidative stress causes ME/CFS or long COVID, only that they appear to be associated with these conditions in existing research. The study does not test whether antioxidant treatments are effective in patients—it only proposes antioxidants as a potential approach worthy of investigation. Correlation of mitochondrial abnormalities with fatigue does not establish causation without intervention studies.